{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T03:12:13Z","timestamp":1778037133361,"version":"3.51.4"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To provide the lowest effective dose and minimize toxicity, our transfusion service initiated the use of a half-dose for all prophylactic inpatient platelet transfusions. The main rationale for this change in dose was the lack of evidence of increased bleeding and mortality in lower-dose platelet transfusion. Since the current platelet dose is not evidence based, and dose and toxicity are linked for most therapeutics, this approach to reducing adverse effects made scientific and clinical sense. In addition, many blood centers have experienced platelet shortages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included nonbleeding patients older than 50\u2009years with a diagnosed hematologic disease who received prophylactic platelet transfusions and were admitted to our inpatient cancer center between November 1, 2023, and January 1, 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Significantly lower volumes of platelets (153 vs 313\u2009mL, P\u2009&amp;lt;\u2009.0001; 95% CI, 153-166) were administered to the study cohort (n\u2009=\u2009310) vs the control (n\u2009=\u2009301). No significant differences were seen in the number of transfusion events per hospitalization of platelets (4.4 vs 4.1, P\u2009=\u2009.7; 95% CI, \u20132.2 to 1.5) and red blood cells (5.9 vs 7.5, P\u2009=\u2009.29; 95% CI, \u20131.4 to 4.7). The mean platelet counts were similar between both groups in pretransfusion (10.3 vs 10 \u00d7 109\/L, P\u2009=\u2009.73; 95% CI, \u20131.8 to 1.3) and posttransfusion (13.8 vs 15.9 \u00d7 109\/L, P\u2009=\u2009.16; 95% CI, \u20130.88 to 5.1). Bleeding event frequency was also similar between both groups (1.6% vs 1.3%, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Half-dose platelets appear to be safe and effective in nonbleeding patients receiving prophylactic transfusions. This strategy reduces patient exposure to potentially harmful higher-dose transfusions without increasing bleeding events or red blood cell transfusions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajcp\/aqag032","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:48:19Z","timestamp":1773233299000},"source":"Crossref","is-referenced-by-count":0,"title":["Prophylactic half-dose platelet transfusion effect on thrombocytopenia, transfusion, and bleeding occurrence in patients with hematologic disease"],"prefix":"10.1093","volume":"165","author":[{"given":"Christine M","family":"Cahill","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Rochester Medical Center , Rochester, NY,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5616-9264","authenticated-orcid":false,"given":"Bianca","family":"Santonastaso","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Rochester Medical Center , Rochester, NY,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madelyn","family":"Gatchell","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Rochester Medical Center , Rochester, NY,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Spector","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Rochester Medical Center , Rochester, NY,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Blumberg","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Rochester Medical Center , Rochester, NY,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phuong-Lan T","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Rochester Medical Center , Rochester, NY,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akua","family":"Asante","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Rochester Medical Center , Rochester, NY,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra","family":"Masel","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Rochester Medical Center , Rochester, NY,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimee","family":"Kievitt","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Rochester Medical Center , Rochester, NY,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Henrichs","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Rochester Medical Center , Rochester, NY,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8491-0279","authenticated-orcid":false,"given":"Majed A","family":"Refaai","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of Rochester Medical Center , Rochester, NY,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"2026050522351876300_aqag032-B1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1160\/TH14-12-1067","article-title":"The role of platelets in inflammation","volume":"114","author":"Thomas","year":"2015","journal-title":"Thromb Haemost"},{"key":"2026050522351876300_aqag032-B2","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1056\/NEJMoa0904084","article-title":"Dose of prophylactic platelet transfusions and prevention of hemorrhage","volume":"362","author":"Slichter","year":"2010","journal-title":"N Engl J Med"},{"key":"2026050522351876300_aqag032-B3","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1212772","article-title":"A no-prophylaxis platelet-transfusion strategy for hematologic cancers","volume":"368","author":"Stanworth","year":"2013","journal-title":"N Engl J Med"},{"key":"2026050522351876300_aqag032-B4","doi-asserted-by":"crossref","first-page":"102610","DOI":"10.1016\/j.transci.2019.06.033","article-title":"Comparison of efficacy of low and high dose prophylactic platelet transfusion therapy in thrombocytopenic haemato-oncology patients","volume":"59","author":"Dhiman","year":"2020","journal-title":"Transfus Apher Sci"},{"key":"2026050522351876300_aqag032-B5","first-page":"CD010984","article-title":"Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation","volume":"2015","author":"Estcourt","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"2026050522351876300_aqag032-B6","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1182\/blood.V92.4.1448","article-title":"Platelet transfusion: a dose-response study","volume":"92","author":"Norol","year":"1998","journal-title":"Blood"},{"key":"2026050522351876300_aqag032-B7","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1111\/j.1537-2995.2006.00979.x","article-title":"An association of soluble CD40 ligand (CD154) with adverse reactions to platelet transfusions","volume":"46","author":"Blumberg","year":"2006","journal-title":"Transfusion"},{"key":"2026050522351876300_aqag032-B8","first-page":"2306","article-title":"The effect of ABO immune complexes on endothelial cell integrity as measured by electric cell-substrate impedance sensing (ECIS) and confocal microscopy","volume":"130","author":"McRae","year":"2017","journal-title":"Blood"},{"key":"2026050522351876300_aqag032-B9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1423-0410.2010.01464.x","article-title":"An association of ABO non-identical platelet and cryoprecipitate transfusions with altered red cell transfusion needs in surgical patients","volume":"101","author":"Refaai","year":"2011","journal-title":"Vox Sang"},{"key":"2026050522351876300_aqag032-B10","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.thromres.2010.10.012","article-title":"Platelet transfusions: impact on hemostasis, thrombosis, inflammation and clinical outcomes","volume":"127","author":"Refaai","year":"2011","journal-title":"Thromb Res"},{"key":"2026050522351876300_aqag032-B11","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1213\/ANE.0000000000006168","article-title":"Patient blood management is a new standard of care to optimize blood health","volume":"135","author":"Goobie","year":"2022","journal-title":"Anesth Analg"},{"key":"2026050522351876300_aqag032-B12","first-page":"e112910","article-title":"Evaluating the importance of patient blood management during COVID-19 pandemic","volume":"11","author":"Chegini","year":"2021","journal-title":"Anesth Pain Med"},{"key":"2026050522351876300_aqag032-B13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1213\/ANE.0000000000006138","article-title":"Patient blood management: improving outcomes for millions while saving billions. What is holding it up?","volume":"135","author":"Hofmann","year":"2022","journal-title":"Anesth Analg"},{"key":"2026050522351876300_aqag032-B14","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1111\/trf.15233","article-title":"The argument(s) for lowering the US minimum required content of apheresis platelet components","volume":"59","author":"Benjamin","year":"2019","journal-title":"Transfusion"},{"key":"2026050522351876300_aqag032-B15","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/asheducation-2015.1.237","article-title":"Bleeding complications in immune thrombocytopenia","volume":"2015","author":"Arnold","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2026050522351876300_aqag032-B16","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1002\/ajh.24585","article-title":"Improved outcomes in acute myeloid leukemia patients treated with washed transfusions","volume":"92","author":"Greener","year":"2017","journal-title":"Am J Hematol"},{"key":"2026050522351876300_aqag032-B17","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/vox.12146","article-title":"Safety of platelet transfusion: past, present and future","volume":"107","author":"Katus","year":"2014","journal-title":"Vox Sang"},{"key":"2026050522351876300_aqag032-B18","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.transci.2015.10.014","article-title":"Platelet microparticles and cancer: an intimate cross-talk","volume":"53","author":"Goubran","year":"2015","journal-title":"Transfus Apher Sci"},{"key":"2026050522351876300_aqag032-B19","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.transci.2015.10.010","article-title":"An overview of the role of microparticles\/microvesicles in blood components: are they clinically beneficial or harmful?","volume":"53","author":"Burnouf","year":"2015","journal-title":"Transfus Apher Sci"},{"key":"2026050522351876300_aqag032-B20","doi-asserted-by":"crossref","first-page":"101022","DOI":"10.1016\/j.tranon.2021.101022","article-title":"Platelet transfusion for cancer secondary thrombocytopenia: platelet and cancer cell interaction","volume":"14","author":"Wang","year":"2021","journal-title":"Transl Oncol"},{"key":"2026050522351876300_aqag032-B21","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1471-2482-14-34","article-title":"Perioperative blood transfusion adversely affects prognosis after resection of lung cancer: a systematic review and a meta-analysis","volume":"14","author":"Luan","year":"2014","journal-title":"BMC Surg"},{"key":"2026050522351876300_aqag032-B22","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/CCM.0000000000002283","article-title":"Liberal versus restrictive transfusion strategy in critically ill oncologic patients: the transfusion requirements in critically ill oncologic patients randomized controlled trial","volume":"45","author":"Bergamin","year":"2017","journal-title":"Crit Care Med"},{"key":"2026050522351876300_aqag032-B23","author":"World Health Organization","year":"2023"},{"key":"2026050522351876300_aqag032-B24","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/trf.16140","article-title":"The current state of the platelet supply in the US and proposed options to decrease the risk of critical shortages","volume":"61","author":"Stubbs","year":"2021","journal-title":"Transfusion"},{"key":"2026050522351876300_aqag032-B25","doi-asserted-by":"crossref","first-page":"476","DOI":"10.5858\/arpa.2024-0102-OA","article-title":"Use of low-dose platelets in actively bleeding patients: a retrospective analysis of a cardiac surgery cohort","volume":"149","author":"Raymond","year":"2025","journal-title":"Arch Pathol Lab Med"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/165\/5\/aqag032\/68223565\/aqag032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/165\/5\/aqag032\/68223565\/aqag032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T02:35:25Z","timestamp":1778034925000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/doi\/10.1093\/ajcp\/aqag032\/8670046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqag032","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,5]]},"article-number":"aqag032"}}